Abuse potential of zomepirac

Rolley E. Johnson, Donald R. Jasinski, Theresa R. Kocher

Research output: Contribution to journalArticle

Abstract

Zomepirac sodium, a nonsteroidal anti- inflammatory analgesic, was compared to morphine sulfate and placebo in an abuse liability study in a postaddiction population. Morphine (15 and 30 mg), but not zomepirac (400 and 800 mg), induced pupillary constriction and characteristic morphinelike subjective effects. The 800-mg dose of zomepirac was discriminated but was not euphorigenic. This study indicates that zomepirac is not likely to be abused.

Original languageEnglish (US)
Pages (from-to)386-389
Number of pages4
JournalClinical Pharmacology and Therapeutics
Volume34
Issue number3
StatePublished - Sep 1983

Fingerprint

Morphine
Non-Steroidal Anti-Inflammatory Agents
Constriction
Placebos
zomepirac
Population

ASJC Scopus subject areas

  • Pharmacology

Cite this

Johnson, R. E., Jasinski, D. R., & Kocher, T. R. (1983). Abuse potential of zomepirac. Clinical Pharmacology and Therapeutics, 34(3), 386-389.

Abuse potential of zomepirac. / Johnson, Rolley E.; Jasinski, Donald R.; Kocher, Theresa R.

In: Clinical Pharmacology and Therapeutics, Vol. 34, No. 3, 09.1983, p. 386-389.

Research output: Contribution to journalArticle

Johnson, RE, Jasinski, DR & Kocher, TR 1983, 'Abuse potential of zomepirac', Clinical Pharmacology and Therapeutics, vol. 34, no. 3, pp. 386-389.
Johnson RE, Jasinski DR, Kocher TR. Abuse potential of zomepirac. Clinical Pharmacology and Therapeutics. 1983 Sep;34(3):386-389.
Johnson, Rolley E. ; Jasinski, Donald R. ; Kocher, Theresa R. / Abuse potential of zomepirac. In: Clinical Pharmacology and Therapeutics. 1983 ; Vol. 34, No. 3. pp. 386-389.
@article{fc279c5fd3634cb9984e08e2d7e21437,
title = "Abuse potential of zomepirac",
abstract = "Zomepirac sodium, a nonsteroidal anti- inflammatory analgesic, was compared to morphine sulfate and placebo in an abuse liability study in a postaddiction population. Morphine (15 and 30 mg), but not zomepirac (400 and 800 mg), induced pupillary constriction and characteristic morphinelike subjective effects. The 800-mg dose of zomepirac was discriminated but was not euphorigenic. This study indicates that zomepirac is not likely to be abused.",
author = "Johnson, {Rolley E.} and Jasinski, {Donald R.} and Kocher, {Theresa R.}",
year = "1983",
month = "9",
language = "English (US)",
volume = "34",
pages = "386--389",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Abuse potential of zomepirac

AU - Johnson, Rolley E.

AU - Jasinski, Donald R.

AU - Kocher, Theresa R.

PY - 1983/9

Y1 - 1983/9

N2 - Zomepirac sodium, a nonsteroidal anti- inflammatory analgesic, was compared to morphine sulfate and placebo in an abuse liability study in a postaddiction population. Morphine (15 and 30 mg), but not zomepirac (400 and 800 mg), induced pupillary constriction and characteristic morphinelike subjective effects. The 800-mg dose of zomepirac was discriminated but was not euphorigenic. This study indicates that zomepirac is not likely to be abused.

AB - Zomepirac sodium, a nonsteroidal anti- inflammatory analgesic, was compared to morphine sulfate and placebo in an abuse liability study in a postaddiction population. Morphine (15 and 30 mg), but not zomepirac (400 and 800 mg), induced pupillary constriction and characteristic morphinelike subjective effects. The 800-mg dose of zomepirac was discriminated but was not euphorigenic. This study indicates that zomepirac is not likely to be abused.

UR - http://www.scopus.com/inward/record.url?scp=0020525855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020525855&partnerID=8YFLogxK

M3 - Article

C2 - 6883915

AN - SCOPUS:0020525855

VL - 34

SP - 386

EP - 389

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 3

ER -